GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » RxSight Inc (NAS:RXST) » Definitions » Net-Net Working Capital

RxSight (RxSight) Net-Net Working Capital : $3.54 (As of Mar. 2024)


View and export this data going back to 2021. Start your Free Trial

What is RxSight Net-Net Working Capital?

In calculating the Net-Net Working Capital (NNWC), Benjamin Graham assumed that a company's accounts receivable is only worth 75% its value, its inventory is only worth 50% of its value, but its liabilities have to be paid in full. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. This is a conservative way of estimating the company's value.

RxSight's Net-Net Working Capital for the quarter that ended in Mar. 2024 was $3.54.

The industry rank for RxSight's Net-Net Working Capital or its related term are showing as below:

RXST's Price-to-Net-Net-Working-Capital is ranked worse than
77.9% of 448 companies
in the Medical Devices & Instruments industry
Industry Median: 6.48 vs RXST: 15.96

RxSight Net-Net Working Capital Historical Data

The historical data trend for RxSight's Net-Net Working Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

RxSight Net-Net Working Capital Chart

RxSight Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Net-Net Working Capital
-17.58 -16.93 4.11 2.16 3.57

RxSight Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Net-Net Working Capital Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.38 3.64 3.69 3.57 3.54

Competitive Comparison of RxSight's Net-Net Working Capital

For the Medical Devices subindustry, RxSight's Price-to-Net-Net-Working-Capital, along with its competitors' market caps and Price-to-Net-Net-Working-Capital data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


RxSight's Price-to-Net-Net-Working-Capital Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, RxSight's Price-to-Net-Net-Working-Capital distribution charts can be found below:

* The bar in red indicates where RxSight's Price-to-Net-Net-Working-Capital falls into.



RxSight Net-Net Working Capital Calculation

RxSight's Net-Net Working Capital (NNWC) per share for the fiscal year that ended in Dec. 2023 is calculated as

Net-Net Working Capital(A: Dec. 2023 )
=(Cash, Cash Equivalents, Marketable Securities+0.75 * Accounts Receivable+0.5 * Total Inventories-Total Liabilities
-Preferred Stock-Minority Interest)/Shares Outstanding (EOP)
=(127.182+0.75 * 20.281+0.5 * 17.421-22.188
-0-0)/36.1395
=3.57

RxSight's Net-Net Working Capital (NNWC) per share for the quarter that ended in Mar. 2024 is calculated as

Net-Net Working Capital(Q: Mar. 2024 )
=(Cash, Cash Equivalents, Marketable Securities+0.75 * Accounts Receivable+0.5 * Total Inventories-Total Liabilities
-Preferred Stock-Minority Interest)/Shares Outstanding (EOP)
=(125.354+0.75 * 21.55+0.5 * 18.7-19.236
-0-0)/37.1618
=3.54

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In calculating the Net-Net Working Capital (NNWC), Benjamin Graham assumed that a company's accounts receivable is only worth 75% its value, its inventory is only worth 50% of its value, but its liabilities have to be paid in full.

In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.

This is a conservative way of estimating the company's value.


RxSight  (NAS:RXST) Net-Net Working Capital Explanation

One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.

Benjamin Graham looked for companies whose market values were less than two-thirds of their net-net value. They are collected under our Net-Net screener.


RxSight Net-Net Working Capital Related Terms

Thank you for viewing the detailed overview of RxSight's Net-Net Working Capital provided by GuruFocus.com. Please click on the following links to see related term pages.


RxSight (RxSight) Business Description

Traded in Other Exchanges
N/A
Address
100 Columbia, Aliso Viejo, CA, USA, 92656
RxSight Inc is a commercial-stage medical technology company dedicated towards improving the vision of patients following cataract surgery. It offers intraocular lens technology that enables doctors to customize and optimize visual acuity for patients after cataract surgery.
Executives
Ilya Goldshleger officer: Chief Operating Officer C/O RXSIGHT, INC., 100 COLUMBIA, ALISO VIEJO CA 92656
Eric Weinberg officer: Chief Commercial Officer C/O RXSIGHT, INC., 100 COLUMBIA, ALISO VIEJO CA 92656
Shweta Maniar director C/O SEASPINE HOLDINGS CORP, 5770 ARMADA DRIVE, CARLSBAD CA 92008
Jesse Anderson Corley director C/O RXSIGHT, INC., 100 COLUMBIA, ALISO VIEJO CA 92656
Kurtz Ronald M Md director, officer: See Remarks C/O RXSIGHT, INC., 100 COLUMBIA, ALISO VIEJO CA 92656
Robert Keith Warner director C/O RXSIGHT, INC., 100 COLUMBIA, ALISO VIEJO CA 92656
Shelley B Thunen officer: Chief Financial Officer C/O RXSIGHT, INC., 100 COLUMBIA, ALISO VIEJO CA 92656
Bakker Juliet Tammenoms director LONGITUDE CAPITAL MANAGEMENT CO., LLC, 800 EL CAMINO REAL, SUITE 220, MENLO PARK CA 94025
Tamara Fountain director C/O RXSIGHT, INC., 100 COLUMBIA, ALISO VIEJO CA 92656
Robert J Palmisano director 110 HARTWELL AVENUE, LEXINGTON MA 02173
Link William J Phd director, 10 percent owner ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
Julie Andrews director 5677 AIRLINE ROAD, ARLINGTON TN 38002
Rajeev M. Shah 10 percent owner 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Peter Kolchinsky 10 percent owner 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Ra Capital Management, L.p. 10 percent owner 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116